利拉鲁肽与达格列净联合治疗2型糖尿病肾病的临床疗效分析

目的分析利拉鲁肽与达格列净联合治疗2型糖尿病肾病的临床疗效。方法回顾分析该院2019年2月—2020年4月期间收治的2型糖尿病肾病患者80例,按治疗方式分组,其中40例接受利拉鲁肽治疗(对照组),另40例接受达格列净联合利拉鲁肽治疗(观察组),比较治疗效果,即疗效、血糖指标、24 h尿总蛋白、24 h尿微量白蛋白、胱抑素C等指标。结果观察组疗效95.00%高于对照组67.50%,差异有统计学意义(P<0.05);比较血糖指标,治疗前组间数据差异无统计学意义(P>0.05),治疗后,观察组糖化血红蛋白、餐后2 h血糖、空腹血糖低于对照组,差异有统计学意义(P<0.05);比较24 h尿总蛋白、24 h尿微量白蛋白、尿微量白蛋白/尿肌酐(ACR)、胱抑素C、同型半胱氨酸,治疗前组间数据差异无统计学意义(P>0.05),治疗后,观察组24 h尿总蛋白、24 h尿微量白蛋白、尿微量白蛋白/尿肌酐(ACR)、胱抑素C、同型半胱氨酸均低于对照组,差异有统计学意义(P<0.05)。结论达格列净联合利拉鲁肽治疗2型糖尿病肾病,可更好地控制患者血糖指标,降低尿蛋白,疗效比单一使用利拉鲁肽治疗更理想。

Analysi s of the Clinical Efficacy of Liraglutide and Dapagliflozin in the Treatment of Type 2 Diabetic Nephropathy

Objective To analyze the clinical efficacy of liraglutide and dapagliflozin in the treatment of type 2 diabetic nephropathy.Methods A retrospective analysis of 80 patients with type 2 diabetic nephropathy admitted to the hospital from February 2019 to April 2020 were grouped according to the treatment method,40 of which received liraglutide treatment(control group),and the other 40 received Dapagliflozin combined with liraglutide treatment(observation group),compare the therapeutic effects,such as curative effect,blood glucose indicators,24 h urine total protein,24 h urine microalbumin,cystatin C and other indicators.Results The curative effect of the observation group was 95.00%,which was higher than that of the control group 67.50%,and the difference was statistically significant(P<0.05);comparing the blood glucose index,the data difference between the groups before treatment was not statistically significant(P>0.05).After treatment,the observation group was glycosylated hemoglobin,2 h blood glucose,fasting blood glucose lower than the control group,and the difference was statistically significant(P<0.05);compare 24 h urine total protein,24 h urine microalbumin,urine microalbumin/urinary creatinine(ACR),cystatin C,homocysteine,data differences between groups before treatment was not statistically significant(P>0.05).After treatment,the observation group’s 24 h urine total protein,24 h urine microalbumin,urine microalbumin/urinary creatinine(ACR),cystatin C,and homocysteine were all lower than those of the control group,and the difference was statistically significant(P<0.05).Conclusion The combination of dapagliflozin and liraglutide in the treatment of type 2 diabetic nephropathy can better control the patient’s blood glucose index and reduce urine protein.The curative effect is more ideal than the single use of liraglutide.